⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 13, 2019Science Translational MedicineOpen Access

IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response

View Full Paper

Ask AI

Bookmark

Share

Abstract

glioma harboring TP53 and ATRX loss could improve the therapeutic efficacy of radiotherapy and, consequently, patient survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Núñez et al. (2019) studied this question.

synapsesocial.com/papers/6a8ce2271af27387482f04ac https://doi.org/10.1126/scitranslmed.aaq1427

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Maintenance of primary tumor phenotype and genotype in glioblastoma stem cellsOriginal Research · 2011 · 237 citations
2Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilitiesOriginal Research · 2018 · 98 citations
3Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaCohort Study · 2016 · 1,073 citations
4<i>IDH1</i>and<i>IDH2</i>Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With<i>NPM1</i>Mutation Without<i>FLT3</i>Internal Tandem DuplicationPrognostic Study · 2010 · 804 citations
5<i>IDH1</i>and<i>IDH2</i>Mutations in GliomasOriginal Research · 2009 · 5,844 citations